Signatera is already in clinical use in the United States ."It is covered by Medicare and reimbursement is already in place for testing," Aleshin said.
He noted that the test may also be useful for monitoring treatment response in patients treated with immunotherapy."It's difficult to see with imaging if a patient is responding to immunotherapy, and ctDNA performs much better for this purpose," he said. Led by Takayuki Yoshino, MD, of the National Cancer Center Hospital East in Kashiwa, Japan, the goal of the study was to prospectively validate and build upon the previously published evidence. The researchers sought to show that postsurgical ctDNA positivity is prognostic of disease recurrence in early-stage colorectal cancer, and they also looked at the impact of postsurgical ctDNA on outcomes, implications for adjuvant chemotherapy selection, and the association between ctDNA and prognosis.
Among the ctDNA-positive patients, 61.4% experienced recurrence, compared with 9.5% of ctDNA-negative patients . This extrapolated to an 18-month DFS of 38.4% vs.90.5%, and this trend was observed across all stages.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ABC - 🏆 471. / 51 Read more »